Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Twist Bioscience's change in inventory for the quarter that ended in Jun. 2026 was $-1.6 Mil. It means Twist Bioscience's inventory
increased by $1.6 Mil
from Mar. 2026 to Jun. 2026 .
Twist Bioscience's change in inventory for the fiscal year that ended in Sep. 2025 was $-4.2 Mil. It means Twist Bioscience's inventory
increased by $4.2 Mil
from Sep. 2024 to Sep. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Twist Bioscience's Days Inventory for the quarter that ended in Jun. 2026 was 56.03.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Twist Bioscience's Inventory Turnover for the quarter that ended in Jun. 2026 was 1.63.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Twist Bioscience's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.29.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Twist Bioscience's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience Change In Inventory Related Terms
Twist Bioscience Change In Inventory Historical Data
* Premium members only.
The historical data trend for Twist Bioscience's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of $-9.2 Mil mean?
Twist Bioscience (TWST) has a Change In Inventory of $-9.2 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Twist Bioscience and its competitors.
Is Twist Bioscience's Change In Inventory too high?
Twist Bioscience's current Change In Inventory is $-9.2 Mil. Overall, Twist Bioscience has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's Change In Inventory compare to BLLN and SHC?
Twist Bioscience's Change In Inventory of $-9.2 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Medical Diagnostics & Research company?
A good Change In Inventory depends on the Medical Diagnostics & Research industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Twist Bioscience and its competitors. Twist Bioscience's current Change In Inventory is $-9.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is $52.17, compared to a current price of $114.81 — trading 120.1% above its estimated fair value. The current Change In Inventory is $-9.2 Mil. Twist Bioscience's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Twist Bioscience (TWST), the current Change In Inventory is $-9.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (TWST) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of $114.81 is trading 120.1% above its estimated GF Value™ of $52.17.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for TWST:
Change In Inventory: $-9.2 Mil
GF Value™: $52.17 vs. price of $114.81 (120.1% above fair value)
No single metric tells the full story. See the TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
69GF Score
Get the complete analysis for TWST
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TWST has been successfully added to your 
